Impaired Hepatic Function research hub

A Phase 1, Open-label, Pharmacokinetic Study of TVB-2640 in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Function.

This study looks at how a new medicine, TVB-2640, is handled by the body in people with healthy livers compared to those with mild, moderate, or severe liver problems. It's an early-stage study to understand the drug better.